Opinion of the Transparency Council – cladrybine
At its meeting on 10 February 2025, the Transparency Council adopted opinion No. 24/2025 on the appropriateness of introducing changes for cladrybine under the B.29 drug program “Treatment of patients with multiple sclerosis (ICD-10: G35)”